Markets:

Overview

News

Currencies

International

Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED

Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc. Common Shares

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Cybin CEO Presenting at Jefferies London Healthcare Conference ↗

November 11, 2021

Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the...

Via Benzinga

Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial ↗

November 09, 2021

Shares plunged, despite a psilocybin-based drug reducing depression in a trial.

Via Investor's Business Daily

Cybin to Release Q2 2021 Results on November 15 ↗

November 09, 2021

Cybin (NYSE:

Via Benzinga

32 Stocks Moving in Tuesday's Pre-Market Session ↗

November 09, 2021

Gainers Dover Motorsports, Inc. (NYSE: DVD) rose 57% to $3.58 in pre-market trading. Luminar Technologies, Inc. (NASDAQ: LAZR) rose 54.2% to $26.98 in pre-market trading after...

Via Benzinga

Cybin Inc. Receives Schedule I Manufacturing License from DEA ↗

November 04, 2021

Cybin (NYSE:

Via Benzinga

64 Biggest Movers From Yesterday ↗

November 09, 2021

Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile...

Via Benzinga

Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression ↗

November 08, 2021

Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive...

Via Benzinga

Cybin's CYB003 Demonstrates Advantages over Oral Psilocybin for Mental Health ↗

November 08, 2021

Cybin (NYSE:

Via Benzinga

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval ↗

November 08, 2021

Detroit Decriminalizes Psychedelics

Via Benzinga

Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules ↗

November 04, 2021

Cybin Inc. (NYSE:CYBN) a company developing novel psychedeli...

Via Benzinga

Cybin Inc. Schedules R&D Briefing to Release Breakthrough Research Findings ↗

November 02, 2021

Cybin (NEO: CYBN) (NYSE:

Via Benzinga

Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation ↗

November 01, 2021

The Week In Psychedelics:

Via Benzinga

Topics Intellectual Property

Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex ↗

October 27, 2021

Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S. Food and Drug Administration (FDA)...

Via Benzinga

Cybin Inc. Announces FDA IND Authorization of Potentially Pivotal Study ↗

October 27, 2021

Cybin (NYSE:

Via Benzinga

Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent ↗

October 26, 2021

The Week In Psychedelics

Via Benzinga

Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up? ↗

October 23, 2021

The psychedelic drug industry is advancing by leaps and bounds, but the stocks have been sliding. Why this disconnect won't last.

Via Talk Markets

Psychedelics Discussed At Benzinga Cannabis Capital Conference: Growth Opportunities, Mental Health & Pharma ↗

October 19, 2021

Ronan Levy, co-founder and executive chairman of Field Trip Ltd (NASDAQ: FTRP), a company developing a network of psychedelics-assisted therapy clinics; Doug Drysdale, CEO,...

Via Benzinga

Topics Cannabis

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021 ↗

October 15, 2021

Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.

Via Talk Markets

6 Psychedelic Stocks With Buy Rating: Why Are They Good Investments? ↗

October 01, 2021

This article by Jason Najum was originally published on

Via Benzinga

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

Four Stocks Disrupting Mental Health To Keep An Eye On At Benzinga's Healthcare Conference ↗

September 30, 2021

The healthcare sector is booming and startups are the driving force behind the innovations that will affect the future of life on earth. ...

Via Benzinga

The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio? ↗

September 21, 2021

We compare and contrast the three psychedelic drug ETFs and assess which investor needs each addresses.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021 ↗

October 05, 2021

Upgrades Wolfe Research upgraded the previous rating for PACCAR Inc (NASDAQ:

Via Benzinga

Cannabis Drug Stocks Have Mirrored Performance Of Psychedelic Drug Stocks To Date In September ↗

September 20, 2021

Which index has outperformed so far in September, the Pure-Play Marijuana-Based Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index?

Via Talk Markets

Topics Cannabis

38 Stocks Moving In Thursday's Mid-Day Session ↗

September 16, 2021

Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the stock on social media. Dutch Bros Inc. (NYSE: BROS...

Via Benzinga

Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗

September 09, 2021

By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...

Via Benzinga

Marijuana Vs. Psychedelic Drug Stocks: Which Out-Performed Last Week? ↗

September 06, 2021

The Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 8 constituents in each of two sub-categories, let's see which out-performed last week.

Via Talk Markets

Topics Cannabis

Buying Cybin Stock Right Now Could Be a Brilliant Move ↗

September 02, 2021

You'll need to be prepared for a long holding period and a hearty helping of risk.

Via The Motley Fool

Topics Law Enforcement

Psychedelic Drug Industry Report Card For 2021 ↗

September 01, 2021

In assessing the psychedelic drug industry, a primary focus for investors is drug development.

Via Talk Markets

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Cybin Inc. Common Shares (NY:CYBN)

Headline News about Cybin Inc. Common Shares

Starting at $3.75/week.

Subscribe Today